Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.52 |
| ▸ | RAB9A | P51151 | 11/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.52 |
| ▸ | MEN1 | O00255 | 8/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.52 |
| ▸ | MAPT | P10636 | 7/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.47 |
| ▸ | RELA | Q04206 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14006520 | 0.81 | SMN1; SMN2 (0.68) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL12297548 | 0.81 | SMN1; SMN2 (0.59) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5025816 | 0.80 | RAB9A (0.70) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL31219369 | 0.76 | GLA (0.74) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL13290891 | 0.76 | GLA (0.74) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL30123733 | 0.75 | SMN1; SMN2 (0.61) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL10081042 | 0.74 | PIK3CG (0.64) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL20380313 | 0.72 | NPC1 (0.75) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL11265618 | 0.72 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL30123601 | 0.71 | HTT (0.65) | NPC1RAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN UNIVERSITY (US) | 2021-01-26 | — | — | US | disclosed |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | CASE WESTERN UNIVERSITY (US) | 2019-10-01 | — | — | US | disclosed |
| EP-2509596-B1 | GAMMA AMINOACIDS FOR TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN UNIVERSITY | 2019-08-22 | — | — | US | disclosed |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190099420-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | CASE WESTERN UNIVERSITY | 2019-04-04 | — | — | US | disclosed |
| US-10208049-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-02-19 | — | — | US | disclosed |
| US-10208049-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-02-19 | — | — | US | disclosed |
| US-10117868-B2 | Systems pharmacology for treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-11-06 | — | — | US | disclosed |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-08-21 | — | — | US | disclosed |
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-08-21 | — | — | US | disclosed |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-08-21 | — | — | US | disclosed |
| US-8722669-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722669-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722669-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-13 | — | — | US | disclosed |
| WO-2013063269-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-22 | — | — | US | disclosed |
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-22 | — | — | US | disclosed |
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, TXNRD2, TXNRD1 | NPC1 333/4885RAB9A 554/4885SMN1; SMN2 2159/4885 |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | GRK1, MTNR1A, MTNR1B | NPC1 1451/4885RAB9A 458/4885SMN1; SMN2 3119/4885 |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | GPR119, ARRB1, GRK1 | NPC1 1897/4885RAB9A 1811/4885SMN1; SMN2 3033/4885 |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | NPC1 1897/4885RAB9A 1811/4885SMN1; SMN2 3033/4885 |
| US-20190099420-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | GRK1, MTNR1A, MTNR1B | NPC1 1451/4885RAB9A 458/4885SMN1; SMN2 3119/4885 |
| US-10117868-B2 | Systems pharmacology for treating ocular disorders | GRK1, MTNR1A, MTNR1B | NPC1 1451/4885RAB9A 458/4885SMN1; SMN2 3119/4885 |
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | NPC1 29/4885RAB9A 432/4885SMN1; SMN2 489/4885 |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, TXNRD2, TXNRD1 | NPC1 333/4885RAB9A 554/4885SMN1; SMN2 2159/4885 |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | NPC1 29/4885RAB9A 432/4885SMN1; SMN2 489/4885 |
| US-10208049-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, NR2E3, LRAT | NPC1 29/4885RAB9A 432/4885SMN1; SMN2 489/4885 |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | NPC1 1897/4885RAB9A 1811/4885SMN1; SMN2 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.